Boston Scientific Receives FDA Approval For Promus Premier(TM) Everolimus ... Wall Street Journal NATICK, Mass., Nov. 25, 2013 /PRNewswire/ -- Continuing to advance leading drug-eluting stent (DES) technology, Boston Scientific Corporation (NYSE: BSX) has received U.S. Food and Drug Administration (FDA) approval for the Promus PREMIER(TM) ... Boston Scientific Gets FDA Approval For Promus Premier Everolimus-EPCCS ... FDA approves next-generation EES BSX scores FDA device approval for drug-eluting stent for coronary artery ... |
